INVENTIVA overview

Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort Topline results from NATiV3 projected in the second half of 2026 and, if positive, expected to be the basis for submission for regulatory approval Daix (France), New York City (New York, United States), April 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral...

Initiation of the clinical development program of lanifibranor in Japan with the dosing of the first participant in Phase 1 study Positive results could support the initiation of a pivotal Phase 3 trial in patients in Japan with MASH The study represents the first significant step of Inventiva’s and Hepalys’s partnership toward the development of lanifibranor in Japan and South Korea Daix (France), New York City (New York, United States), Tokyo (Japan), February 20, 2025 – Inventiva...

Revenues of €9.2 million for the full year of 2024 Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million structured financing closed with aggregate gross proceeds of €116 million Last patient screened in the NATiV3 Phase 3 clinical trial of lanifibranor in MASH early January 2025 and randomization of the last patient expected within the first half of 2025 Pipeline prioritization plan presented to the workers council to focus exclusively on...

Daix (France), New York City (New York, United States), January 22, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today announced that the results from its Proof-of-Concept trial evaluating lanifibranor in...

Daix (France), New York City (New York, United States), December 17, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced that Frédéric Cren, CEO and cofounder...

Cash and cash equivalents at €13.9 million, as of September 30, 2024. Revenues of €1.3 million for the first nine months of 2024. On July 18, 2024, Inventiva issued royalty certificates for an amount of €20.1 million. Considering the receipt of €94.1 million in gross proceeds from the closing of the first part of the first tranche of the equity raise announced on October 14, 2024 2 and the receipt of the $10 million milestone payment under the amended license and collaboration agreement...

Data will be presented on Monday, November 18 th as a late breaker poster at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024 in San Diego. LEGEND achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo. 50% percent of patients saw their HbA1c levels below 6.5% at week 24 following treatment with lanifibranor alone or in combination with...

Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“ Inventiva ” or the “ Company ”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“ MASH ”) and other diseases with significant unmet medical needs, today announces that the Autorité des marchés financiers (the “ AMF ”) has...